Compare National Beverage Corp. (FIZZ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Sana Biotechnology Inc — how do they compare? National Beverage Corp. trades at $30.56 (market cap $2.89B), while Sana Biotechnology Inc trades at $3.83 (market cap $1.13B). The key difference: National Beverage Corp. is far larger — about 2.6× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| FIZZ | SANA | |
|---|---|---|
Market Cap | $2.89B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $5.92 |
52-Week Low | $30.53 | $2.68 |
Enterprise Value | $2.60B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $30.45, down 1.9% on the day, with a bearish technical signal and recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margin improved to 15.56% in 2025. The company announced a special dividend of $3.25 per share, payable in July 2026, but faces declining LaCroix volumes and muted growth prospects.
The outlook is cautious due to stalled growth and bearish analyst sentiment, with 50% of coverage rating Sell. Risks include competitive pressures and weak volume trends, though the dividend provides some shareholder return. Upside appears limited without a clear catalyst for revenue acceleration.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
